This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Keytruda
  • /
  • Study to Evaluate the Safety and Efficacy of Two D...
Clinical trial

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Read time: 1 mins
Last updated:1st Aug 2013

This is a three-arm study to evaluate the safety and efficacy of two dosing schedules of pembrolizumab (MK-3475) compared to ipilimumab for the treatment of ipilimumab-naïve participants with unresectable or metastatic melanoma.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Estimated Enrollment: 645
Study Start Date: August 2013
Estimated Study Completion Date: March 2016
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)

- Experimental:
Pembrolizumab Every 2 Weeks
- Experimental: Pembrolizumab Every 3 Weeks
- Active Comparator: Ipilimumab

Related journal: Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Category Value
Study start date 2013-08-01

View full details